HAIFA, Israel, Jan. 27, 2011 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) announced that it has priced a firm commitment underwritten public offering of 11,000,000 units, with each unit consisting of one share of the company's common stock and one warrant to purchase 0.4 of a share of common stock, at a purchase price of $3.25 per unit for an aggregate gross offering amount of $35.8 million. The offering is expected to close on or about February 1, 2011, subject to customary closing conditions. Each warrant will be exercisable for a period of five years commencing six months following the issuance thereof at an exercise price of $4.20. The company has also granted the underwriters a 30-day option to purchase up to 1,650,000 shares of common stock and warrants to purchase up to 660,000 shares of common stock to cover over-allotments, if any. Oppenheimer & Co. Inc. is acting as the sole bookrunner and Needham & Company, LLC is acting as co-lead manager for the offering. Maxim Group LLC and National Securities Corp are in the selling group for the offering. Leader Capital Markets Ltd. advised the company as did Roth Capital Partners, LLC.
Pluristem Announces Pricing Of Public Offering Of Common Stock And Warrants To Purchase Common Stock
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.